BEGIN:VCALENDAR VERSION:2.0 PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4// BEGIN:VEVENT UID:20250918T064129EDT-7555RvGpoI@132.216.98.100 DTSTAMP:20250918T104129Z DESCRIPTION:Abstract:\n\nThe G枚tte lab has a longstanding interest in the s tudy of viral polymerases. The focus has been on the biological function o f these enzymes and the discovery and development of antiviral drugs. Whil e at 黑料不打烊 (2000-2014)\, his work was centered around human immunodeficie ncy virus type 1 reverse transcriptase (HIV-1 RT)\, human cytomegalovirus (HCMV) DNA polymerase and hepatitis C virus (HCV) RNA-dependent RNA polyme rase (RdRp). He contributed to the discovery of novel classes of HIV-1 RT inhibitors and studied the genetic\, biochemical and structural basis of d rug resistance. Since 2024\, at the University of Alberta\, he changed dir ections and started to focus on polymerases of viruses with high epidemic potential. His lab was the first to express\, purify and show inhibition o f the Ebola virus polymerase complex\, the 450 kDa Crimean-Congo hemorrhag ic fever virus (CCHFV) polymerase and the SARS-CoV-2 polymerase complex. T hey have now established a library of ~50 viral polymerases representing i mportant families of retroviruses\, DNA and RNA viruses. This is a unique platform for the evaluation of polymerase inhibitors\, which was proven su ccessful in the early days of the pandemic. G枚tte鈥檚 lab and collaborators from Gilead Sciences published in February and April of 2020 the mechanism of action of remdesivir\, a C-linked adenosine analog that targets the po lymerase of coronaviruses. These studies showed that remdesivir\, when com pared with other available nucleotide analogs\, was by far the most potent compound against the polymerase of the new virus. Remdesivir was later ap proved as the first antiviral drug for the treatment of COVID-19. More rec ently\, he contributed to the development of a novel nucleosides with pote nt activity against a broader spectrum of respiratory viruses. However\, e ffective nucleoside analogs that target the polymerase of influenza viruse s remain elusive.聽聽聽\n\n聽\n\nBio:\n\nMatthias G枚tte obtained his PhD degre e in 1997 at the Max-Planck-Institute for Biochemistry in Martinsried\, Ge rmany. In 2000\, following his postdoctoral training with Mark Wainberg at the Lady Davis Institute for Medical Research in Montreal\, he joined the faculty at 黑料不打烊 University in the Department of Microbiology & Immunolo gy. In 2014\, he accepted the position as chair of the Medical Microbiolog y & Immunology Department (MMI) at the University of Alberta (UofA) in Edm onton\, Alberta. G枚tte has been recognized for his expertise in the study of viral polymerases\, antiviral drugs and the broader field of pandemic p reparedness. Early in the COVID-19 pandemic\, his lab elucidated the mecha nism of action of the nucleoside analog remdesivir. In 2020\, he was invit ed to the 2020 National Institutes of Health (NIH) SARS-CoV-2 Antiviral Th erapeutics Summit and served on the Canadian COVID-19 Therapeutics Task Fo rce. In 2022-2025\, he was an investigator of three NIH-funded Antiviral D rug Discovery (AViDD) Centres for Pathogens of Pandemic Concern\, led by t he University of North Carolina (UNC)\, Scripps Research in La Jolla\, and the University of California San Francisco (UCSF). In 2023\, he completed his second term as the chair of MMI and is currently the Director of UofA 鈥檚 pandemic preparedness program SPP-ARC (Striving for Pandemic Preparedne ss - The Alberta Research Consortium).聽聽\n DTSTART:20250923T170000Z DTEND:20250923T183000Z LOCATION:OM 10\, Maass Chemistry Building\, CA\, QC\, Montreal\, H3A 0B8\, 801 rue Sherbrooke Ouest SUMMARY:Chemical Society Seminar: Matthias Gotte (Belleau Lecture)- Nucleos ide Analog Inhibitors of Viral Polymerases: From HIV-1 to SARS-CoV-2 URL:/science/channels/event/chemical-society-seminar-m atthias-gotte-belleau-lecture-nucleoside-analog-inhibitors-viral-367781 END:VEVENT END:VCALENDAR